Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anticholium® Per Se a Randomized, Double-blind, Placebo-controlled, Monocentric Trial on the Adjunctive Use of Physostigmine Salicylate (Anticholium®) in Perioperative Sepsis and Septic Shock

NCT03013322 is registered in ClinicalTrials.gov with University Hospital Heidelberg as lead sponsor.

NCT NCT03013322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03013322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anticholium® Per Se a Randomized, Double-blind, Placebo-controlled, Monocentric Trial on the Adjunctive Use of Physostigmine Salicylate (Anticholium®) in Perioperative Sepsis and Septic Shock
Lead sponsor
University Hospital Heidelberg
Phase
Not applicable
Overall status
Completed
Start date
January 28, 2015
Completion date
February 18, 2017
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

perioperative period, sepsis, shock, septic